[ad_1]
Daiichi Sankyo Firm Q2 FY2025 Earnings Name October 31, 2025 2:30 AM ET
Firm Contributors
Hiroyuki Okuzawa – President, CEO, Consultant Director
Joseph Kenneth Keller – Head, Oncology
Ken Takeshita – Head of Analysis and Growth Unit
Koji Ogawa – Senior Govt Officer, Head of World Company Planning & Administration, CFO
Convention Name Contributors
Steve Barker – Jefferies
Kazuaki Hashiguchi – Daiwa Securities
Shinichiro Muraoka – Morgan Stanley
Tony Ren – Macquarie
Fumiyoshi Sakai – UBS
Miki Sogi – Bernstein
Seiji Wakao – JPMorgan
Hidemaru Yamaguchi – Citi
Kentaro Asakura
Women and gents, we want to begin FY2025 Q2 monetary outcomes presentation. My title is Asakura, in command of Company Communication.
On this presentation session, we’re going to use each Japanese and English. We’ve simultaneous interpretation service out there so please ensure you click on on the language button to decide on the language of your choice. We’ve Japanese, English, and authentic audio. If you choose authentic audio, ought to be capable of hear authentic audio. On the Zoom display, we’re going to current each Japanese and English presentation materials. For the dwell streaming, we’re going to current Japanese presentation materials. Our company web site, IR library, earnings call-related materials web page carries presentation materials each in Japanese and English.
Let me introduce in the present day’s audio system. We’ve Consultant Director and CEO, Okuzawa. We’ve Head of World R&D, Takeshita. We’ve Ken Keller, who’s the Director and Oncology Enterprise Head. We’ve CFO, Ogawa. First, Okuzawa and Takeshita will give you the reason of the highlights of the Q2 outcomes.
We’re going to obtain questions from traders and analysts by 5:00 PM. Media individuals can begin asking questions individually from 10 minutes previous 5:00 PM. Right now’s session goes to be audio recorded. I want to ask to your
[ad_2]
